Nkarta, Inc.
NASDAQ:NKTXBiotechnology
+$0.09 today
- Market cap
- $82.37M
- Beta
- 0.90
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$1.35
Volume 0.81M
Average 0.75M
NKTX Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Nkarta, Inc.NASDAQ: NKTX
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow outflow grows to $6K
Q1 FY2026 financing cash flow was $6K, compared with $0 a year earlier. Trailing-twelve-month financing cash flow was $147K. Over 3 fiscal years it compounded at -91.4% a year.
Context
- Financing cash flow increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly financing cash flow holds near $6K or moves back toward the trailing-twelve-month quarterly average of $36.75K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 141K USD
- Year-over-year change
- -99.9%
- 4-year CAGR
- -41.5%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 141K | -99.9% |
| FY2024 | 2024-12-31 | 226.08M | +32618.4% |
| FY2023 | 2023-12-31 | 691K | -99.7% |
| FY2022 | 2022-12-31 | 219.01M | +18120.6% |
| FY2021 | 2021-12-31 | 1.2M | — |
Financing Cash Flow vs competitors
How NKTX compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +180.8% is the 3rd highest of 8, against a peer median of +44.8%.
- Over three fiscal years its annual growth of -91.4% compares with a peer median of +20.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $579.28M USD | +999.4% | +62.6% | — | |
| LTM Mar 2026 | $109.5M USD | +6044.6% | -1.3% | — | |
| LTM Mar 2026 | $71.76M USD | +44.8% | +112.4% | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $34.39M USD | -17.4% | +20.1% | — |
| LTM Mar 2026 | $20.24M USD | +94.0% | +64.8% | 109.9% | |
| LTM Mar 2026 | $5.49M USD | +24.7% | -15.8% | 86.9% | |
| LTM Mar 2026 | CHF 1.3M CHF | -109.0% | -9.9% | — | |
| LTM Mar 2026 | $147K USD | +180.8% | -91.4% | — | |
| Peer median (excluding NKTX) | — | +44.8% | +20.1% | 98.4% | |
Competitors are the stored peer set for NKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (86.08M) | (113.84M) | (117.5M) | (108.79M) | (104.08M) |
| Depreciation & Amortization | 1.76M | 2.64M | 5.87M | 2.24M | 4.61M |
| Deferred Income Tax | 3.24M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 14.46M | 16.86M | 17.2M | 16.73M | 8.56M |
| Change in Working Capital | (1.64M) | 33.74M | 10.93M | (12.16M) | (435K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.79M | 2.76M | 4.22M | (4.47M) | 2.46M |
| Other Working Capital | (4.44M) | 30.98M | 6.7M | (7.69M) | (2.9M) |
| Other Non-Cash Items | 337K | 3.61M | (2.65M) | 2.29M | 2.65M |
| Operating Cash Flow | (67.93M) | (57M) | (86.16M) | (99.7M) | (88.7M) |
| Capital Expenditures | (5.03M) | (47.11M) | (28.15M) | (4.41M) | (1.21M) |
| Acquisitions (Net) | (37.56K) | 137.58K | 0 | 0 | 0 |
| Purchases of Investments | (227.28M) | (385.89M) | (260.23M) | (406.38M) | (238.57M) |
| Sales of Investments | 264.84M | 248.31M | 367.4M | 281.23M | 340.09M |
| Other Investing Activities | 37.56K | (137.58K) | 0 | 0 | 0 |
| Investing Cash Flow | 32.53M | (184.69M) | 79.02M | (129.56M) | 100.32M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 1.2M | 217.17M | 691K | 225.07M | 141K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 1.84M | 0 | 1.01M | 0 |
| Financing Cash Flow | 1.2M | 219.01M | 691K | 226.08M | 141K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (34.19M) | (22.68M) | (6.45M) | (3.17M) | 11.76M |
| Free Cash Flow | (72.95M) | (104.11M) | (114.31M) | (104.11M) | (89.91M) |
Nkarta, Inc.
NASDAQ:NKTX
Intrinsic Alpha fair value
Locked
Current Price
$1.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.